Credit: Shutterstock photoOn Wednesday, Charles River Labs International ( CRL ) got a positive adjustment to its Relative Strength ( RS ) Rating , from 69 to 72.
[ibd-display-video id=2385970 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Charles River Labs International can continue to show renewed price strength and hit that benchmark.
Looking For The Best Stocks To Buy And Watch? Start Here
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear a proper buy point .
Top and bottom line growth moved higher last quarter. Earnings were up 10%, compared to 8% in the prior report. Revenue increased from 8% to 9%.
The company holds the No. 8 rank among its peers in the Medical-Research Equipment/Services industry group. PRA Health Sciences ( PRAH ), Quintiles IMS ( IQV ) and Catalent ( CTLT ) are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
